Phase IIa exploratory study of two doses of levosalbutamol hydrochloride tablets in moderate inflammatory bowel disease

Phase 2, open-label trial of levalbuterol in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease (4 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Proportion of subjects achieving symptom relief or endoscopic remission at 8 weeks. Planned start Aug 2024; status: not yet recruiting.